Home > Neurology > EAN 2020 > Headache and Pain > Long-term cardiovascular safety of erenumab

Long-term cardiovascular safety of erenumab

Presented By
Dr Stewart Tepper, Geisel School of Medicine, USA
Conference
EAN 2020
In an analysis of 4 randomised trials and their open-label extensions, the safety of erenumab was assessed [1]. The frequency of cardiovascular and cerebrovascular adverse events (AEs) was comparable to that of placebo seen over 12 weeks. There was no increased emergence of AEs in up to 5 years of follow-up. Dr Stewart Tepper (Geisel School of Medicine, USA) presented the results of the post-hoc analysis of AEs in erenumab users with episodic or chronic migraine with or without a history of aura. During the 12-week double-blind treatment phase, 2,443 patients were treated with erenumab (70 mg/140 mg once monthly) or placebo. Of these, 1,140 (47%) had a history of aura. Dr Tepper noted that vascular risk factors were more prominent in the aura subgroup. At baseline, ≥2 cardiovascular risk factors were present in 35% of patients with aura and 27% of patients without. Cardiovascular and cerebrovascular AE rates were low throughout the controlled and op...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on